Recombinant human parathyroid hormone

Status:

Do Not Prescribe (DNP)

Decision Date:

April 2020

Comments

Recombinant human parathyroid hormone for treating hypoparathyroidism (NICE TA625) has been terminated therefore it has been classified as DO NOT PRESCRIBE (DNP) (Decision date - June 2020)

search again